Andexanet alfa is associated with lower in-hospital mortality compared to 4-factor prothrombin complex concentrate in patients with factor Xa inhibitor-related major bleeding

Paul P. Dobesh, Pharm.D.
University of Nebraska Medical Center, College of Pharmacy
Omaha, NE, U.S.

The safety and efficacy of andexanet alfa compared to 4-Factor PCC (4F-PCC) for in-hospital mortality in patients with Factor Xa inhibitor-related major bleeding was assessed. Dobesh, Pharm.D., discusses results from the trial that focused on patients experiencing intracranial and gastrointestinal hemorrhage while on Factor Xa inhibitors. This study presents the adjusted odds of in-hospital mortality to be lower by 50% for patients treated with andexanet alfa in comparison to 4F-PCC. Conclusions of good hemostatic efficacy in patients with Factor Xa-associated major bleeding and the relative impact on bleed management are discussed.